Martina Dicker
Overview
Explore the profile of Martina Dicker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Ascui G, Dicker M, Riffelmacher T, Chandra V, Schmiedel B, et al.
Nat Commun
. 2025 Mar;
16(1):2577.
PMID: 40089498
Genome wide association studies (GWAS) identify many risks for Crohn's disease (CD), including a site near the metabolism gene laccase domain containing 1 (LACC1). We previously found this site near...
2.
Mathews I, Saminathan P, Henglin M, Liu M, Nadig N, Fang C, et al.
medRxiv
. 2024 Aug;
PMID: 39148854
Immune related adverse events (irAEs) after immune checkpoint blockade (ICB) therapy occur in a significant proportion of cancer patients. To date, the circulating mediators of ICB-irAEs remain poorly understood. Using...
3.
Dicker M, Li Y, Giles D, Verstichel G, Castelan V, Ascui-Gac G, et al.
Front Immunol
. 2022 Nov;
13:1034648.
PMID: 36389671
Colitis is characterized by an exacerbated intestinal immune response, but the genetic and other mechanisms regulating immune activation remain incompletely understood. In order to identify new pathways leading to colitis,...
4.
Eschweiler S, Ramirez-Suastegui C, Li Y, King E, Chudley L, Thomas J, et al.
Nature
. 2022 May;
605(7911):741-746.
PMID: 35508656
Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies. Although studies in mouse models...
5.
Riffelmacher T, Giles D, Zahner S, Dicker M, Andreyev A, McArdle S, et al.
Mucosal Immunol
. 2021 Feb;
14(3):679-690.
PMID: 33568785
Inflammatory bowel disease is characterized by an exacerbated intestinal immune response, but the critical mechanisms regulating immune activation remain incompletely understood. We previously reported that the TNF-superfamily molecule TNFSF14 (LIGHT)...
6.
Shin Y, Castilho A, Dicker M, Sadio F, Vavra U, Grunwald-Gruber C, et al.
Plant Biotechnol J
. 2016 Jul;
15(2):197-206.
PMID: 27421111
Plants are attractive hosts for the production of recombinant glycoproteins for therapeutic use. Recent advances in glyco-engineering facilitate the elimination of nonmammalian-type glycosylation and introduction of missing pathways for customized...
7.
Dicker M, Maresch D, Strasser R
Bioengineered
. 2016 Jun;
7(6):484-489.
PMID: 27333379
IgA nephropathy (IgAN) is a common autoimmune disease that is characterized by formation and deposition of IgA1-containing immune complexes frequently leading to end-stage kidney disease. The IgA1 in these immune...
8.
Dicker M, Tschofen M, Maresch D, Konig J, Juarez P, Orzaez D, et al.
Front Plant Sci
. 2016 Feb;
7:18.
PMID: 26858738
The production of therapeutic antibodies to combat pathogens and treat diseases, such as cancer is of great interest for the biotechnology industry. The recent development of plant-based expression systems has...
9.
Dicker M, Strasser R
Expert Opin Biol Ther
. 2015 Jul;
15(10):1501-16.
PMID: 26175280
Introduction: Glycans are increasingly important in the development of new biopharmaceuticals with optimized efficacy, half-life, and antigenicity. Current expression platforms for recombinant glycoprotein therapeutics typically do not produce homogeneous glycans...
10.
Dicker M, Schoberer J, Vavra U, Strasser R
Methods Mol Biol
. 2015 Jun;
1321:249-67.
PMID: 26082228
Plants are attractive expression hosts for the production of recombinant glycoprotein therapeutics. The quality and efficiency of these biopharmaceuticals are very often influenced by the glycosylation profile. Consequently, approaches are...